Inhibition of Cyclin D-CDK4/6 axis in PTEN-deficient neoplasias
Dosil Garcia, Maria Alba
Mirantes Barbeito, Cristina
Eritja Sánchez, Núria
Felip Nogués, Isidre
Navaridas Fernández de Bobadilla, Raúl
Gatius Calderó, Sònia
Santacana Espasa, Maria
Colás, Eva
Moiola, Cristian P.
Schoenenberger, Joan Antoni
Encinas Martín, Mario
Garí Marsol, Eloi
Matias-Guiu, Xavier
Dolcet Roca, Xavier
2018-06-12T07:47:35Z
2018-06-12T07:47:35Z
2017-04-28
2018-06-12T07:47:38Z
PTEN is one of the most frequently mutated genes in human cancers. The frequency of PTEN alterations is particularly high in endometrial carcinomas. Loss of PTEN leads to dysregulation of cell division, and promotes the accumulation of cell cycle complexes such as cyclin D1-CDK4/6, which is an important feature of the tumour phenotype. Cell cycle proteins have been presented as key targets in the treatment of the pathogenesis of cancer, and several CDK inhibitors have been developed as a strategy to generate new anticancer drugs. Palbociclib (PD-332991) specifically inhibits CDK4/6, and it has been approved for use in metastatic breast cancer in combination with letrazole. Here, we used a tamoxifen-inducible Pten knockout mouse model to assess the antitumour effects of cyclin D1 knockout and CDK4/6 inhibition by palbociclib on endometrial tumours. Interestingly, both cyclin D1 deficiency and palbociclib treatment triggered shrinkage of endometrial neoplasias. In addition, palbociclib treatment significantly increased the survival of Pten-deficient mice, and, as expected, had a general effect in reducing tumour cell proliferation. To further analyse the effects of palbociclib on endometrial carcinoma, we established subcutaneous tumours with human endometrial cancer cell lines and primary endometrial cancer xenografts, which allowed us to provide more translational and predictive data. To date, this is the first preclinical study evaluating the response to CDK4/6 inhibition in endometrial malignancies driven by PTEN deficiency, and it reveals an important role of cyclin D-CDK4/6 activity in their development.
This work was supported by grants FIS PI13/00263, SAF2016-80157-R, PI13/01701, 2009SGR794,Grupos estables AECC (AECC2011), RETICS(RD12/0036/0013), Catalunya contra el cáncer, Programa de intensificación de la investigación, Instituto Carlos III, and BFU 2013-42895-P. MAD holds a predoctoral fellowship from Ministerio de Educación
Inglés
Endometrial carcinoma; Palbociclib; PTEN
Wiley
info:eu-repo/grantAgreement/MINECO//SAF2016-80157-R/ES/
info:eu-repo/grantAgreement/MINECO//BFU2013-42895-P/ES/ESTUDIO DE LOS MECANISMOS QUE REGULAN LA ACTIVIDAD CITOPLASMATICA DEL COMPLEJO CYCD1-CDK4. CARACTERIZACION DE SU RELEVANCIA FUNCIONAL EN MAMIFEROS/
Versió postprint del document publicat a: https://doi.org/10.1002/path.4896
Journal of Pathology, 2017, vol. 242, núm. 2, p. 152-164
(c) Pathological Society of Great Britain and Ireland, 2017
Documents de recerca [17848]